Actively Recruiting

Phase 3
Age: 6Months - 17Years
All Genders
NCT05709028

Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections

Led by University of Sydney · Updated on 2024-06-06

300

Participants Needed

5

Research Sites

208 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Urinary tract infections (UTIs) are among the most common bacterial infections in children. Up to 50% of UTI's are caused by multi-drug resistant ESBL-producing gram negative bacteria that do not respond to treatment with oral penicillin's or cephalosporins. Instead, children often require hospital admission to receive broad-spectrum intravenous antibiotics when they may otherwise be safely managed at home; resulting in prolonged hospital stays and an increased use of health resources. Fosfomycin is a broad-spectrum antibiotic discovered in 1969 that remains susceptible to a large number of organisms due to its low international use. Fosfomycin can be prepared as an oral solution with an orange/tangerine flavour and is currently approved for use in females \>12 years old. Despite extensive evidence of its efficacy in adults and safety in neonates, the use of fosfomycin in children remains limited and fosfomycin is not currently licensed for use in children \<12 years old in Australia. The aim of this clinical trial is to compare the use of oral fosfomycin against standard of care antibiotics for the treatment of antibiotic resistant urinary tract infections in children. The main questions the trial aims to answer are: 1. Is oral fosfomycin non-inferior in efficacy to the current standard of care for the treatment of antibiotic-resistant urinary tract infections in children? 2. Is oral fosfomycin a safe and well-tolerated antibiotic in children? 3. What is the best dosing regimen of oral fosfomycin for the treatment of antibiotic-resistant UTIs in children?

CONDITIONS

Official Title

Fosfomycin Versus Standard of Care in Children With Antibiotic-resistant Urinary Tract Infections

Who Can Participate

Age: 6Months - 17Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Children aged 6 months to under 18 years
  • Symptoms consistent with a clinical diagnosis of urinary tract infection
  • Urine culture showing predominant growth of a bacterial uropathogen (≥10^6 CFU/L or ≥10^3 CFU/mL) with ≥10x10^6 white blood cells on microscopy
  • Bacterial pathogen is a non-pseudomonal gram-negative organism commonly causing UTIs in children (Escherichia coli, Proteus spp., Klebsiella spp., Enterobacter spp., Serratia spp., or Citrobacter spp.)
  • Pathogen shows resistance to all oral penicillins and oral first- and second-generation cephalosporins or presumed resistance based on testing
  • Patient has received less than 48 hours of antibiotics active against the urinary pathogen before enrollment
Not Eligible

You will not qualify if you...

  • Evidence of bacteraemia due to the same urinary pathogen in the current illness
  • Infection at a secondary site such as meningitis or endocarditis
  • Signs of sepsis requiring inotropic support or more than 20ml/kg fluid bolus
  • Inability to tolerate or absorb oral antibiotics
  • Severe renal insufficiency with creatinine clearance under 10ml/min/1.73m²
  • Known allergy to fosfomycin
  • Physician decision that trial enrollment is not in the child's best interest

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 5 locations

1

Sydney Childrens Hospital

Sydney, New South Wales, Australia, 2031

Actively Recruiting

2

The Children's Hospital at Westmead

Sydney, New South Wales, Australia, 2145

Not Yet Recruiting

3

Queensland Children's Hospital

Brisbane, Queensland, Australia, 4101

Actively Recruiting

4

Royal Childrens Hospital

Melbourne, Victoria, Australia, 3052

Actively Recruiting

5

Perth Children's Hospital

Perth, Western Australia, Australia, 6000

Actively Recruiting

Loading map...

Research Team

M

Michelle L Harrison

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here